₦airaland Forum

BullBearMkt:
@aremso, curiosity made me check EYEN chart. Just wondering why you bought into the stock? Is it because of the massive fall?
EYEN outlook still bearish. YES! you can exit at 0.25 - smart plan; but risky!

Chopping serious flogs from shorties

aremso:
Chopping serious flogs from shorties

...as you know, you win some and loose some; what matter most is your risk management

BullBearMkt:
...as you know, you win some and loose some; what matter most is your risk management

Sure bro, but stiil optimistics to exit at 0.20-0.25 but today trashing not a childs pla

Stock to buy and hold forever
1. Amazon
Amazon (AMZN -1.87%) may be the ultimate growth company, as it's a leader in two high-growth markets: e-commerce and cloud computing. On top of this, Amazon is going all in on the latest promising area that some say will revolutionize the world, much like the telephone or the Internet. I'm talking about artificial intelligence (AI). Amazon is using AI to improve its own business through efficiency gains, and it's selling AI products and services to customers through its cloud computing unit, Amazon Web Services (AWS).

All of this has helped Amazon build a solid earnings track record, generally reporting billions of dollars in revenue and profit quarter after quarter. In e-commerce, Amazon's competitive moat is strong: It's built an extensive fulfillment network and an attractive subscription program that's kept customers loyal. And the company now continues to make deliveries faster and faster -- to save on costs and please the customer. That's a win-win situation.


NASDAQ: AMZN
Amazon
Today's Change
(-1.87%) -US$3.80
Current Price
US$199.08
As for cloud computing and AI, they go hand-in-hand. AI has helped AWS reach an annual revenue run rate of $110 billion. And this is key because AWS traditionally has been Amazon's profit driver.

Today, Amazon is trading for 40x forward earnings estimates. This isn't dirt cheap, but it's reasonable considering the company's strengths in such high growth areas and potential for the earnings momentum to continue well into the future.



2. Chewy
Chewy (CHWY 2.61%), like Amazon, is an e-commerce company, but this player specializes in one particular area -- serving your furry friends. Chewy sells everything from pet food and toys to prescription drugs and pet health insurance. And the company recently expanded into a brick-and-mortar business with the launch of veterinary clinics known as Chewy Vet Care. Finally, Chewy also brings in revenue through sponsored ads, a business that's in its early days but is exceeding the company's expectations.

What I like most about Chewy is a program that clearly shows its customers' loyalty -- and therefore offers us visibility on future revenue. This is Chewy's Autoship, a service that allows you to choose items you use regularly to be automatically reordered and shipped to you at a specific time. Autoship sales have steadily made up more than 75% of total sales quarter after quarter, and in the most recent quarter that percentage was more than 78%. Another number showing how much customers like Chewy is the net sales per active customer -- it climbed 6% to reach a record of $565 in the quarter.


NYSE: CHWY
Chewy
Today's Change
(2.61%) US$0.91
Current Price
US$35.52
Chewy also has a solid financial situation, with no debt and $695 million in cash, and a focus on managing operating expenses. And the company predicts its gross margin, today at about 29%, will fluctuate, but over time it will widen as higher-margin parts of the business grow.

All of this makes Chewy, today trading for 25x forward earnings estimates, an exciting growth player to buy and hold for the long term.

Don’t miss this second chance at a potentially lucrative opportunity
Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this.

On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:

Nvidia: if you invested $1,000 when we doubled down in 2009, you’d have $378,269!*
Apple: if you invested $1,000 when we doubled down in 2008, you’d have $43,369!*
Netflix: if you invested $1,000 when we doubled down in 2004, you’d have $476,653!*

© 1995 - 2024 The Motley Fool. All rights reserved.

Celestialsword:
Stock to buy and hold forever
1. Amazon
Amazon (AMZN -1.87%) may be the ultimate growth company, as it's a leader in two high-growth markets: e-commerce and cloud computing. On top of this, Amazon is going all in on the latest promising area that some say will revolutionize the world, much like the telephone or the Internet. I'm talking about artificial intelligence (AI). Amazon is using AI to improve its own business through efficiency gains, and it's selling AI products and services to customers through its cloud computing unit, Amazon Web Services (AWS).

All of this has helped Amazon build a solid earnings track record, generally reporting billions of dollars in revenue and profit quarter after quarter. In e-commerce, Amazon's competitive moat is strong: It's built an extensive fulfillment network and an attractive subscription program that's kept customers loyal. And the company now continues to make deliveries faster and faster -- to save on costs and please the customer. That's a win-win situation.


NASDAQ: AMZN
Amazon
Today's Change
(-1.87%) -US$3.80
Current Price
US$199.08
As for cloud computing and AI, they go hand-in-hand. AI has helped AWS reach an annual revenue run rate of $110 billion. And this is key because AWS traditionally has been Amazon's profit driver.

Today, Amazon is trading for 40x forward earnings estimates. This isn't dirt cheap, but it's reasonable considering the company's strengths in such high growth areas and potential for the earnings momentum to continue well into the future.



2. Chewy
Chewy (CHWY 2.61%), like Amazon, is an e-commerce company, but this player specializes in one particular area -- serving your furry friends. Chewy sells everything from pet food and toys to prescription drugs and pet health insurance. And the company recently expanded into a brick-and-mortar business with the launch of veterinary clinics known as Chewy Vet Care. Finally, Chewy also brings in revenue through sponsored ads, a business that's in its early days but is exceeding the company's expectations.

What I like most about Chewy is a program that clearly shows its customers' loyalty -- and therefore offers us visibility on future revenue. This is Chewy's Autoship, a service that allows you to choose items you use regularly to be automatically reordered and shipped to you at a specific time. Autoship sales have steadily made up more than 75% of total sales quarter after quarter, and in the most recent quarter that percentage was more than 78%. Another number showing how much customers like Chewy is the net sales per active customer -- it climbed 6% to reach a record of $565 in the quarter.


NYSE: CHWY
Chewy
Today's Change
(2.61%) US$0.91
Current Price
US$35.52
Chewy also has a solid financial situation, with no debt and $695 million in cash, and a focus on managing operating expenses. And the company predicts its gross margin, today at about 29%, will fluctuate, but over time it will widen as higher-margin parts of the business grow.

All of this makes Chewy, today trading for 25x forward earnings estimates, an exciting growth player to buy and hold for the long term.

Don’t miss this second chance at a potentially lucrative opportunity
Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this.

On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:

Nvidia: if you invested $1,000 when we doubled down in 2009, you’d have $378,269!*
Apple: if you invested $1,000 when we doubled down in 2008, you’d have $43,369!*
Netflix: if you invested $1,000 when we doubled down in 2004, you’d have $476,653!*

© 1995 - 2024 The Motley Fool. All rights reserved.

Bro. All my year on nse to me was wasted if I had discovered US same yrs on nse I would have stopped 9-5 rat race but I thank God I will still get there as long as there is life and good health.

aremso:
Bro. All my year on nse to me was wasted if I had discovered US same yrs on nse I would have stopped 9-5 rat race but I thank God I will still get there as long as there is life and good health.

good observation,it's not too and never late,since you've discovered the gold mine, you can start mining

BullBearMkt:
...as you know, you win some and loose some; what matter most is your risk management

Closed at 13% and currently doing 18% post market. my exit still remains 0.25-0.30 that is around 100-200% I will wait it

Celestialsword:
good observation,it's not too and never late,since you've discovered the gold mine, you can start mining

Yes oo bro, I told my bro to buy mtem he entered 0.40+ dipped 0.38 post market gold mining is 58% gain it will likely pump tomorrow have told him to set sell limit

aremso:
Yes oo bro, I told my bro to buy mtem he entered 0.40+ dipped 0.38 post market gold mining is 58% gain it will likely pump tomorrow have told him to set sell limit

That's Great

aremso:
Closed at 13% and currently doing 18% post market. my exit still remains 0.25-0.30 that is around 100-200% I will wait it

yes,one of the greatest secret in this trade is PATIENCE

EYEN +33% PM! very funny market, will set my sell limit according to how premarket will move. Very funny market trashed the other day 70% 2 days later chop another 20% may now run 100-200%

TARGET TECHNICAL ANALYSIS EARLY MARKET COMMENTS 22 NOVEMBER 2024
Many stocks are in overbought are, need to wait for pullback. We will not chase any stock, we will wait for pullback. Today we want to watch the market, if some of the stocks in our watchlist experience strong pullback we will buy (COIN, _ _ _, _ _ _, _ _ _ ), for now we are waiting to see a Good set up.

2 Innovative Stocks That Could Deliver

Iovance Biotherapeutics has developed a nifty approach to treating cancer.
Recursion Pharmaceuticals is trying to solve a problem all drug developers face.

Many of Wall Street's largest and most successful stocks became so thanks to innovation. It's too late to get in on the ground floor with those that are already well-established leaders in their fields, but there are plenty of smaller, highly innovative companies that could deliver excellent returns as they gain in prominence. It's not a sure thing, of course -- such stocks often carry a fair amount of risk.

However, for those who don't mind that risk, it's worth considering companies that fit the parameters. In that spirit, let's discuss two in the healthcare sector that could make breakthroughs and deliver market-beating returns along the way: Iovance Biotherapeutics (IOVA 4.49%) and Recursion Pharmaceuticals (RXRX 3.82%).


NASDAQ: IOVA
Iovance Biotherapeutics
Today's Change
(4.49%) US$0.37
Current Price
US$8.61
1. Iovance Biotherapeutics
Iovance Biotherapeutics is a cancer-focused biotech. The company develops therapies based on tumor-infiltrating lymphocytes (TILs). TILs are a kind of disease-fighting cell that can recognize and destroy cancer cells, and they naturally exist in all of us. Iovance harnesses the power of TILs by extracting them from each patient, manufacturing personalized treatments, and reinserting them back inside the patient.

It's not a simple procedure, but it's produced some exciting results already. In February, Iovance earned approval from the U.S. Food and Drug Administration for Amtagvi, the first therapy for advanced previously treated melanoma (a type of skin cancer). The company estimates a potential U.S. market of 20,000 annual cases for Amtagvi. Iovance will also seek regulatory approvals in other countries, including Canada, several in Europe, and Australia.

Iovance's financial results aren't impressive yet. Revenue in the third quarter was $58.6 million, but that was exponentially better than the $469,000 reported in the year-ago period. Iovance also made progress on the bottom line; its net loss per share of $0.28 was much better than the net loss per share of $0.46 recorded in the prior-year quarter.

It takes time to manufacture TIL therapies like Amtagvi -- about 34 days, in fact. So the company has likely just begun making headway into the U.S. market for its latest medicine. With approval from other countries, its addressable market will significantly expand.

Furthermore, Iovance has a rich pipeline. It's seeking many label expansions for Amtagvi, while developing other brand-new TIL treatments. Iovance Biotherapeutics' innovative approach to treating cancer could prove highly lucrative, and allow it to deliver excellent performance over the long run.


NASDAQ: RXRX
Recursion Pharmaceuticals
Today's Change
(3.82%) US$0.22
Current Price
US$5.97
2. Recursion Pharmaceuticals
Developing drugs is difficult and expensive. The process has become slower, even with technological progress, a phenomenon known as Eroom's law (the reverse of Moore's law). Recursion Pharmaceuticals is trying to change that using an operating system (OS) powered by artificial intelligence (AI).

The company built a virtual lab where different clinical compounds are constantly tested in a human gene library; the most promising ones are chosen to undergo clinical trials. The company claims to spend far less time and money on selecting products to send to clinical trials.

Recursion currently has several products across phase 2 studies for which it will release data in the next year or so. One of them, REC-994, posted positive results in a phase 2 study for cerebral cavernous malformation, when clusters of irregular blood vessels form in the nervous system. The drug can cause severe health problems, so it will still be a while before it or others among Recursion's candidates can be approved.

If it proves successful across the board, Recursion will likely be able to license its OS to other drug developers, in addition to making money from its own medicines. The company's goal of significantly reducing the time and money it takes to develop drugs could prove incredibly lucrative.

Investors should never dive headfirst into a stock without considering the downsides, no matter how innovative a company seems. Here are some of the risks that come with investing in these two biotech stocks.

Iovance's approach is exciting, but the 34 days it takes to manufacture Amtagvi is a significant drawback. The company could also experience clinical or regulatory setbacks, a risk that's more severe for smaller drugmakers.

The same can be said about Recursion Pharmaceuticals -- it still doesn't have a single drug on the market, despite how promising its platform seems.

These two stocks do have significant upside potential. But even for those who can handle the volatility, the heightened risk means investors would want to initiate a small position in one or both stocks at first. Investors can always add more shares over time as (or if) Iovance and Recursion prove themselves.


© 1995 - 2024 The Motley Fool. All rights reserved.

TECHNICAL ANALYSIS COMMENTS FOR WEEK ENDED 22 NOVEMBER AND PLAN FOR NEXT WEEK
It was a good week for the market. Blockchain and tech industries did well. The shout about this market at the moment is all about AI.

Some interesting things being y about AI is that NVDA seems to have taken over the leadership and may be difficult for others to catch up. Let us take the new area of quantum computing into consideration (no company can take away anything from NVDA here). So for now a good stock to keep in our watch is SMCI (the company is likely to get out of the current crisis soon).

For our caucus members, I am sure we are happy, if anyone is unhappy with being a caucus member, I may refund part of the support/subscription you have paid. And equally if you have benefited from the group, please tell others including this forum. We have so much to give l, but we want to avoid information overload. If I have my way, I will recommend just 2 or maximum of 4 stocks on our daily watchlist. And as I emphasised, there is a better way to be Warren Buffet, just make sure you buy some covered call ETF ,(we know the name of our main ETF), buy the ones paying monthly or weekly dividend and you will not run short of money to trade. To be continued later (forum like this is not for long story, especially when we are not doing copy and paste, you are getting information you can use now and will put money in your wallet. By the way I did not buy the $7 stock that will pay $1 dividend in the next few days (less than 1 week) as described by send is not the major consideration for buying a stock. The stock does not have capital appreciation potential, we made about 30% in SOUN in under 2weels, so if I see a gain like this, dividend becomes secondary. But I may still buy the 1$ dividend stock if market turns bearish on Monday, our chart from trading plan blueprint will tell us the best decision
.

1 Brilliant Growth Stock to Buy Now and Hold

Pockets of today's stock market appear overheated as the bull market rumbles on.
However, there are still companies trading for reasonable valuations with long-term tailwinds.
Airbnb's trend model and terrific financial results could make it a long-term winner.
Motley Fool Issues Rare “All In” Buy Alert
The stock market indexes recently made new all-time highs. A resilient economy, interest rates that should trend down, enthusiasm for an expected corporate-friendly incoming administration, enthusiasm for artificial intelligence (AI), and high-flying tech stocks like Nvidia and Microsoft all play a role in this bull market.

Investors should exercise some caution at these levels. Remember that 2021 euphoria quickly turned to dread in 2022. There are pockets of the market that resemble 2021 now. For instance, Palantir's stock trades for 56 times sales and over 160 times forward earnings. It's a terrific company, but this is a nosebleed valuation by any measure.

However, some companies still trade for reasonable valuations with long-term positive trends. Here is one to consider.

Don't sleep on Airbnb
Vacation habits are changing. Younger generations book vacation rentals at a higher rate than older generations, who stick more to traditional hotels. As shown below, the number of vacation rental users will rise 25% from 2024 to 2029.


The trend means that Airbnb (ABNB 3.06%) has a long-term tailwind. Airbnb is also highly successful now.

Revenue hit $3.7 billion last quarter on 10% year-over-year growth, and operating income reached $1.4 billion on fantastic 37% growth. However, what I like most about the company is the ability to produce free cash flow. Airbnb operates with a lean business model and doesn't have significant capital expenditures (capex) needs, so much of its revenue falls into the company's pocket. Of the $10.8 billion sales over the past 12 months, $4.1 billion was converted to free cash flow, a terrific 38% margin.

Having tremendous free cash flow allows Airbnb to fund growth, maintain a fortress balance sheet, and repurchase shares. As of the third quarter, the company reported $11.3 billion in cash and investments against just $2 billion in long-term debt. The company also repurchased $2.6 billion in shares through three quarters of 2024, amounting to more than 3% of the company's current market cap.


Airbnb stock trades at a similar valuation to its rival Booking Holdings (BKNG -0.65%) based on free cash flow, as shown below.


Airbnb is trading slightly below its recent average and well below recent peaks.

Both are terrific investment options; however, Airbnb's market cap is around half of Booking's, so it has more room to compound.

The most significant risk to Airbnb is regulatory. Many localities and homeowners associations have rules limiting short-term rentals. Airbnb works proactively with policymakers to craft mutually beneficial regulations to mitigate the risk.

Airbnb will benefit from the long-term trend toward vacation rentals. The rapid rise in users and its top-notch financial results make the stock an excellent long-term pick.

Don’t miss this second chance at a potentially lucrative opportunity
Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this.

On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves.
© 1995 - 2024 The Motley Fool. All rights reserved.

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below are Strong Buys. Each stock received a new Buy rating recently and has a significant upside as well.


Here are today’s top stock picks, according to analysts.


KinderCare Learning Companies – KLC provides early childhood education and childcare services in the United States. Today, upgraded the stock’s rating to Buy with a price target of $30. In the last three months, six out of the eight Top Analysts covering the stock have rated it a Buy. Taken together, their 12-month price targets imply an upside of over 60%.

Nvidia – NVDA is a global technology company that provides graphics processing units (GPUs), computing, and advanced solutions. Yesterday, reiterated a Buy rating on the stock with a price target of $160. In the last three months, 36 out of the 39 Top Analysts covering the stock have rated it a Buy. Altogether, their 12-month price targets imply an upside of over 23%.


indie Semiconductor – This company provides automotive semiconductors and software solutions. Yesterday, maintained a Buy rating on the stock with a price target of $6. In the last three months, all four Top Analysts covering the stock have rated it a Buy. Taken together, their 12-month price targets imply an upside of about 51%.

TipRanks ranks financial analysts according to the success rates of their ratings and the average return on each of their ratings. The Top Analysts have each earned a five-star ranking, thanks to the accuracy and profitability of their ratings over time.

Danger in biotech stocks SAVA from $35-4 in just one day due to failure in their trial mad ooo

TARGET TECHNICAL ANALYSIS EARLY MARKET COMMENTS 18 NOVEMBER 2024
Market is likely to be volatile till the end of the week, so we should relax, wait to buy pullbacks in the stocks in our watchlist. The themes in play now: QUANTUM COMPUTING, _ _ _ _ _ , _ _ _ _ _ in general, buy pullbacks in these industries. Today we give a material of reference on the flying car industry, just focus on _ _ _ _ _ _

Wishing all the best. At the moment the market is looking sweet. Let us manage our postions well. Profits must not trun to loss (prepare to take profits along the way and do not go countrend, wait if necessary for trend to return)

BuchyD:
Calm down bro.... It's also one of the fastest way to be financially ruined. It could swing both ways.

To cap what you said here SAVA was doing I think around 35 or so and both PM and Regular hours sava moved from 35-3.8$ in just a single day because of their failed PH3 trial. That is why the market is not for the faint hearted and the lazy dudes. NSE is for such people but however, if one put efforts and map out strategies sure is VERY ACHIEVABLE and REWARDING. Part of my strategies is to have watch list and I monitor their price action any time it gets to my destination i jump in I have set prices and I don't buy above that just imagine those that bought at $30 and the nest day investment of 30k now 4k assumed it was 1k units bought. Imagine having to go through over 150 stocks is not for lazy dudes

They have beaten my EYEN black and why but Mr. Eyen says it not over until it is over. Was gaining 23% earlier. 100-200% gain my target, paytienctly waiting.

MARKET IS TELLING US TODAY THAT NOT EVERYDAY IS CHRISTMAS
Today we took some profits and we want to wait on the sideline till Friday. It takes maturity to keep your money in your wallet with all the noice around. So today we keep our cash!!![b][/b]

Where are these comrades:

Sgtponzihater
Henrimoto

aremso:
Danger in biotech stocks SAVA from $35-4 in just one day due to failure in their trial mad ooo

Know when to jump in and out..... 😁😂

Lexusgs430:
Know when to jump in and out..... 😁😂

I love that bro, that was why I said if one knows what he or she is doing and one map out strategies US stocks market is highly rewarding. Know what you are doing with God grace too you will stand before the kings and not mean men

aremso:
I love that bro, that was why I said if one knows what he or she is doing and one map out strategies US stocks market is highly rewarding. Know what you are doing with God grace too you will stand before the kings and not mean men

Diversification to foreign markets, is the only sure antidote to financial freedom.....

Four key ingredients - :

- Time (patience).....
- Research tools......
- Appetite for risks.....
- Funds to invest......

Exposure to only the Nigerian stock markets, only favours moneybags..... 😁

Lexusgs430:
Diversification to foreign markets, is the only sure antidote to financial freedom.....

Four key ingredients - :

- Time (patience).....
- Research tools......
- Appetite for risks.....
- Funds to invest......

Exposure to only the Nigerian stock markets, only favours moneybags..... 😁

God bless you bro can't love this less that is the only financial freedom Arena. Only market where if you know what u are doing your $500 can turn $5k with time if u know what you are doing.

For dividend hunters NAT currently 14.93 DY but it can still do 20% DY with time

aremso:
Danger in biotech stocks SAVA from $35-4 in just one day due to failure in their trial mad ooo

Is it advisable to buy it at this price since it's low? I'll be awaiting your response. Thanks

fungirl89:
Is it advisable to buy it at this price since it's low? I'll be awaiting your response. Thanks

Is the failed PH3 trial that caused the down movements of the price and can still go down a bit though I may be wrong, when the dust settles I think it will bounce back gradually because they still have $147m to re enter again with time. Same Happened to TCRT last year though it was around 0.45 when the trial failed lost about 70% but guys still made over 100% gain , same happened to EYEN their trials failed last week loosing 75% in a day and tried hard to recover then they announced direct offering which took it down to 0.079 but gained 22% yesterday and can still do 100% gain wt time so I believe SAVA when it finally settles it will bounce back the guys behind it are too ambitious.

Good Afternoon Experts…
Please is this a good time to bank on SAVA stocks

9JaSweet:
Good Afternoon Experts…
Please is this a good time to bank on SAVA stocks

It will bounce back gradually if u can be paytiently paytience it will do 100% gain wt time. They have $147m cash to go for another clinical trials

Wall Street sees ‘no alternative’ to U.S. stocks in 2025. Here’s why.

U.S. stocks are expected to continue their streak of world-beating returns in 2025, according to Wall Street strategists.

Large-capitalization U.S. stocks have outperformed virtually all comers over the past 15 years. According to some of the world’s largest investment banks, that is unlikely to change in 2025.

Wall Street analysts have recommended that investors continue to favor shares of the biggest American companies as the S&P 500 index
SPX

looks likely to deliver a total return north of 25% for the second-straight year, a rare accomplishment.

Teams at Deutsche Bank, Goldman Sachs Group, UBS Group, Barclays, Société Générale and JPMorgan Chase & Co. have all recommended that investors focus on the U.S. next year, although some see pockets of value abroad as well.


Most expect the biggest opportunities could be found in shifting market leadership, as investors increasingly diversify away from the Big Tech stocks that dominated the market in 2023 and 2024. Many, including J.P. Morgan’s global markets strategy group led by Dubravko Lakos-Bujas, see financials and utilities as potential beneficiaries.

Although Lakos-Bujas also believes Japanese stocks look compelling, he is much more downbeat on the outlook for the eurozone and emerging markets.

That is not to say there aren’t risks, even in the U.S.

High valuations for the biggest American firms and lingering questions about the incoming policy agenda in Washington could knock the rally off track, or at least introduce more volatility. Rising Treasury yields are also making some nervous, as Trump’s tariff agenda is widely expected to be inflationary.

But a still-strong economy and the lopsided benefits of the artificial-intelligence revolution should continue to favor U.S. stocks.

“The U.S. exceptionalism story could face turbulence and heightened volatility on the back of policy changes in 2025, but opportunities are likely to outweigh risks,” JPMorgan’s Lakos-Bujas said in a report.


The chorus of bullish calls comes as domestic stocks see their share of the global equity market climb to its highest level since late 2001, according to FactSet data, which showed the U.S. market capitalization accounted for more than 50% of the value in the global equity market.

One strategist, Albert Edwards at SocGen, even recently invoked a once-popular acronym — “TINA,” which stands for “there is no alternative” — to describe the perception that U.S. stocks appear to be the only game in town.

Valuations are high, but so are earnings expectations
Most bullish Wall Street strategists touted the myriad advantages harbored by the biggest U.S. firms. Superior earnings growth could continue to push prices higher and justify the recent multiple expansion that has pushed valuations higher.

“The earnings expectation in the U.S. is quite healthy,” said Venu Krishna, chief U.S. equity strategist at Barclays, in an interview with MarketWatch.

While Big Tech should continue to account for the bulk of this growth, other firms are slowly but surely catching up.

“The fulcrum for earnings strength remains centered on Big Tech. But directionally, the rest of the market is moving along the right path, although at a much slower pace than expected.”

The incoming Trump administration’s preference for corporate tax cuts and deregulation could help further pad companies’ bottom lines, while boosting the economy with more deficit spending.

A stock picker’s market
One common theme was dispersion — the notion that the sectors and companies leading the market higher in 2025 could look different from what investors have grown accustomed to in 2023 and 2024. Lakos-Bujas said uneven performance among sectors, styles, themes and countries could create a stock picker’s market.

This has already started to take shape during the second half of 2024, as more sectors have joined in the rally. Financials have even soared ahead of information technology, boosted by expectations surrounding Trump’s deregulation agenda.

To be sure, Wall Street professionals haven’t completely dismissed the benefits of investing abroad. Some have pointed out that international stocks haven’t been very effective as a diversifier lately.

But others, including a team from JPMorgan’s asset-management business led by Chief Global Strategist David Kelly, argued that low valuations in foreign markets are simply too compelling to pass up.

His colleague, Lakos-Bujas acknowledged the possibility that a convergence trade could begin later in 2025, driven by the yawning gap in valuations and a shifting global outlook.

“In the meantime, lack of a quality substitute to U.S. equities remains the reality,” he said.

American (tech) exceptionalism
For decades now, the U.S. economy has been the locus of global technology innovation.

In the past, this ”tech exceptionalism” — as Krishna called it — meant pioneering the development and use of the internet. Today, it means being at the forefront of trends involving artificial intelligence and cloud computing.

This is unlikely to change soon, which is one reason why Krishna expects U.S. markets will continue to dominate. Although substantial uncertainty remains about the return on companies’ investments in artificial intelligence, over time, it will likely boost productivity and make U.S. firms even more profitable.

Recently, the U.S. economy has also proven resilient to some of the pressures that have afflicted the eurozone and China. Even as the Federal Reserve hiked interest rates aggressively to combat a powerful burst of inflation, the U.S. labor market has seen only a modest slowdown.

According to the latest data, GDP grew at 2.8% clip during the third quarter, faster than other developed markets, even as a longstanding slump in manufacturing activity persisted.

Even if the pace of global economic growth were to slow next year, as many expect, U.S. stocks could continue to benefit.

That is because weaker growth abroad makes U.S. stocks even more attractive to foreign investors, according to strategists at UBS Group.

American households also have more of their net worth tied up in stocks than their peers abroad, which helps to magnify the economic boost from the “wealth effect” when the market is rising, the UBS team said.

“The positive wealth effect of the stock market is higher in the U.S. than elsewhere because household ownership of equities is much higher than in other countries,” the UBS team said.

Strategists at Deutsche Bank recently unveiled a 2025 year-end price target of 7,000 for the S&P 500, one of the more bullish forecasts on Wall Street.

Where the team sees risks ahead, they are mostly tied to Trump’s policy agenda. Things could go south if the new administration decides to pursue aggressive across-the-board import tariffs.

Barring this, Deutsche expects a second Trump administration will help boost corporate profits and the broader economy, while his trade policies could make it even more difficult for other economies and markets to keep up.

Risks remain
It is worth noting that Wall Street’s expectations for how things might play out during the coming year rarely pan out, especially when the consensus is so strong, and few appear willing to rock the boat with bold calls. At least, that was the case in 2023, when a bull market in U.S. stocks emerged more quickly than many professionals had expected.

Brent Donnelly, president of Spectra Markets, said that most of the year-ahead outlooks he has seen appeared to extrapolate out what has already been happening during the second half of 2024.

“I will write much more about the 2025 outlook, but for now it seems that forecasters are herding around a base case that looks like an extrapolation of 2024,” Donnelly said in commentary recently shared with MarketWatch.

“This seems off base to me given the brand-new shock and awe administration that will kick off with leaks in the first few weeks of January and new policies shortly thereafter.”

That could mean that the real opportunities await those willing to go against the consensus.


Copyright © 2024 MarketWatch, Inc. All rights reserved